Literature DB >> 22480537

Successful treatment of eosinophilic esophagitis with ciclesonide.

Shauna Schroeder, David M Fleischer, Joanne C Masterson, Erwin Gelfand, Glenn T Furuta, Dan Atkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22480537      PMCID： PMC3816103          DOI： 10.1016/j.jaci.2012.03.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

1.  Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51.

Authors:  Julie M Caldwell; Carine Blanchard; Margaret H Collins; Philip E Putnam; Ajay Kaul; Seema S Aceves; Catherine A Bouska; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-04       Impact factor: 10.793

2.  Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis.

Authors:  Alex Straumann; Sebastien Conus; Lukas Degen; Stephanie Felder; Mirjam Kummer; Hansjürg Engel; Christian Bussmann; Christoph Beglinger; Alain Schoepfer; Hans-Uwe Simon
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

3.  Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma.

Authors:  David S Pearlman; William E Berger; Edward Kerwin; Craig Laforce; Sudeep Kundu; Donald Banerji
Journal:  J Allergy Clin Immunol       Date:  2005-10-10       Impact factor: 10.793

Review 4.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

5.  Once-daily ciclesonide in children: efficacy and safety in asthma.

Authors:  Erwin W Gelfand; John W Georgitis; Michael Noonan; Michael E Ruff
Journal:  J Pediatr       Date:  2006-03       Impact factor: 4.406

6.  Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.

Authors:  Kai Richter; Frank Kanniess; Christian Biberger; Ruediger Nave; Helgo Magnussen
Journal:  J Clin Pharmacol       Date:  2005-02       Impact factor: 3.126

7.  Population pharmacokinetics and pharmacodynamics of ciclesonide.

Authors:  S Rohatagi; V Arya; K Zech; R Nave; G Hochhaus; B K Jensen; J S Barrett
Journal:  J Clin Pharmacol       Date:  2003-04       Impact factor: 3.126

8.  In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.

Authors:  Michael Stoeck; Richard Riedel; Günther Hochhaus; Dietrich Häfner; José M Masso; Beate Schmidt; Armin Hatzelmann; Degenhard Marx; Daniela S Bundschuh
Journal:  J Pharmacol Exp Ther       Date:  2004-01-12       Impact factor: 4.030

9.  Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.

Authors:  Seema S Aceves; John F Bastian; Robert O Newbury; Ranjan Dohil
Journal:  Am J Gastroenterol       Date:  2007-06-20       Impact factor: 10.864
  9 in total
  24 in total

Review 1.  Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches.

Authors:  Bharati Kochar; Evan S Dellon
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-12       Impact factor: 3.869

2.  Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

Authors:  Bridget K Butz; Ting Wen; Gerald J Gleich; Glenn T Furuta; Jonathan Spergel; Eileen King; Robert E Kramer; Margaret H Collins; Emily Stucke; Colleen Mangeot; W Daniel Jackson; Molly O'Gorman; J Pablo Abonia; Scott Pentiuk; Philip E Putnam; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2014-04-22       Impact factor: 22.682

Review 3.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

Review 4.  Eosinophilic esophagitis: current treatment.

Authors:  Matthew Redd; Ron Schey
Journal:  Dig Dis Sci       Date:  2012-09-22       Impact factor: 3.199

5.  Eosinophilic esophagitis: historical perspective on an evolving disease.

Authors:  Stephen E Attwood; Glenn T Furuta
Journal:  Gastroenterol Clin North Am       Date:  2014-03-24       Impact factor: 3.806

Review 6.  Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.

Authors:  Ikuo Hirano; Seema S Aceves
Journal:  Gastroenterol Clin North Am       Date:  2014-04-16       Impact factor: 3.806

7.  Effect of proton pump inhibitor on esophageal eosinophilia.

Authors:  Shauna Schroeder; Kelley E Capocelli; Joanne C Masterson; Rachel Harris; Cheryl Protheroe; James J Lee; Glenn T Furuta
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-02       Impact factor: 2.839

Review 8.  Eosinophilic esophagitis.

Authors:  Evan S Dellon
Journal:  Gastroenterol Clin North Am       Date:  2012-12-27       Impact factor: 3.806

9.  Emerging therapeutic options for eosinophilic esophagitis.

Authors:  Timothy Dougherty; Sindu Stephen; Marie L Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-02

10.  Eosinophilic gastrointestinal diseases--clinically diverse and histopathologically confounding.

Authors:  Seema Aceves; Ikuo Hirano; Glenn T Furuta; Margaret H Collins
Journal:  Semin Immunopathol       Date:  2012-07-29       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.